Download the slides

---

Related articles :

• ENCORE
• EFV vs RPV
  • ECHO-THRIVE
  • STAR
• EFV vs ETR
  • SENSE
• EFV vs DOR
  • DRIVE-AHEAD

---

Table of contents

Comparison of NNRTI vs NNRTI
DRIVE-AHEAD Study: DOR/3TC/TDF vs EFV/FTC/TDF
Reference : Squires KE. IAS 2017, Abs. TUAB0104LB
Last update : 04/09/2017

Dr Anton Pozniak
Chelsea and Westminster Hospital
London, UK

• In treatment-naïve adults with HIV-1 infection, DOR/3TC/TDF administered once daily demonstrated:
  • Antiviral potency with non-inferior efficacy to EFV/FTC/TDF regardless of baseline HIV-1 RNA
  • Low rate of resistance, with only 1.6% of participants developing resistance to any study drug through W48
• DOR/3TC/TDF was generally well tolerated and safe:
  • Neuropsychiatric profile superior to EFV/FTC/TDF, as measured by lower proportion of participants with neuropsychiatric adverse events in categories of dizziness, sleep disorders and disturbances, and altered sensorium
  • Lipid profile superior to EFV/FTC/TDF, as assessed by difference from baseline in fasting LDL-C and non-HDL-C

Design :

* Randomisation was stratified by HIV RNA (< or > 100 000 c/mL) at screening and chronic hepatitis B or C

• DOR/3TC/TDF : 1 tablet qd as STR

Objectives :

• Non inferiority of DOR at W48: % HIV RNA < 50 c/mL by intention to treat, snapshot analysis (lower margin of the 95% CI for the difference = - 10%, 90% power)
• Superiority of DOR for neuropsychiatric adverse events by W48

Baseline characteristics and patient disposition :

Primary endpoint: HIV RNA < 50 c/mL at W48 (ITT, snapshot)

• HIV RNA < 50 c/mL at W48 (observed failure approach)
  • Baseline HIV RNA ≤ 100 000 c/mL: DOR: 90.6% vs EFV: 91.1 %
  • Baseline HIV RNA > 100 000 c/mL: DOR: 81.2 % vs EFV: 80.8 %

Virologic response to treatment at week 48 by subgroups :

• Definition
  • Non response: HIV RNA ≥ 200 c/mL at W24 or W36 or confirmed HIV RNA ≥ 50 c/mL at W48
  • Rebound: confirmed HIV RNA ≥ 50 c/mL after obtaining HIV RNA < 50 c/mL

* NNRTI mutations : Y188L; V106I, F227C; V106V/I, H221H/Y, F227C; F227C; V106A, P225H, Y318Y/F; V106M/T, F227C/R ; NRTI mutations : M41L, M184V; M184V; M184V; K65R; K65K/R, M184V
** NNRTI mutations : K103N; K103N, E138E/G; K103N; G190E; K103N; K103N, M230L; G190E; K103N, V108V/I, T369T/A/I/V; K103N; K103N; K101K/N, K103N, P225P/H ; NRTI mutations : V118I, M184V; M184V; M184V; M184V, K219K/E; K65K/R, M184M/I

Adverse events, %

% with Predefined Neuropsychiatric Adverse Events at W48

Fasting Lipids (mg/dL): Change from Baseline at W48

 

Back to Table of Contents